Mapping from SIBDQ to EQ-5D-5L for patients with inflammatory bowel disease

Author:

Steiner Isa MariaORCID,Bokemeyer BerndORCID,Stargardt TomORCID

Abstract

AbstractObjectiveClinical studies commonly use disease-specific measures to assess patients’ health-related quality of life. However, economic evaluation often requires preference-based utility index scores to calculate cost per quality-adjusted life-year (QALY). When utility index scores are not directly available, mappings are useful. To our knowledge, no mapping exists for the Short Inflammatory Bowel Disease Questionnaire (SIBDQ). Our aim was to develop a mapping from SIBDQ to the EQ-5D-5L index score with German weights for inflammatory bowel disease (IBD) patients.MethodsWe used 3856 observations of 1055 IBD patients who participated in a randomised controlled trial in Germany on the effect of introducing regular appointments with an IBD nurse specialist in addition to standard care with biologics. We considered five data availability scenarios. For each scenario, we estimated different regression and machine learning models: linear mixed-effects regression, mixed-effects Tobit regression, an adjusted limited dependent variable mixture model and a mixed-effects regression forest. We selected the final models with tenfold cross-validation based on a model subset and validated these with observations in a validation subset.ResultsFor the first four data availability scenarios, we selected mixed-effects Tobit regressions as final models. For the fifth scenario, mixed-effects regression forest performed best. Our findings suggest that the demographic variables age and gender do not improve the mapping, while including SIBDQ subscales, IBD disease type, BMI and smoking status leads to better predictions.ConclusionWe developed an algorithm mapping SIBDQ values to EQ-5D-5L index scores for different sets of covariates in IBD patients. It is implemented in the following web application:https://www.bwl.uni-hamburg.de/hcm/forschung/mapping.html.

Funder

Gemeinsame Bundesausschuss

Universität Hamburg

Publisher

Springer Science and Business Media LLC

Subject

Health Policy,Economics, Econometrics and Finance (miscellaneous)

Reference57 articles.

1. Kaplan, G.G., Windsor, J.W.: The four epidemiological stages in the global evolution of inflammatory bowel disease. Nat. Rev. Gastroenterol. Hepatol. 18, 56–66 (2021). https://doi.org/10.1038/s41575-020-00360-x

2. Ng, S.C., Shi, H.Y., Hamidi, N., Underwood, F.E., Tang, W., Benchimol, E.I., Panaccione, R., Ghosh, S., Wu, J.C.Y., Chan, F.K.L., Sung, J.J.Y., Kaplan, G.G.: Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet Lond. Engl. 390, 2769–2778 (2017). https://doi.org/10.1016/S0140-6736(17)32448-0

3. Shivashankar, R., Tremaine, W.J., Harmsen, W.S., Loftus, E.V.: Incidence and prevalence of Crohn’s disease and ulcerative colitis in Olmsted County, Minnesota from 1970 through 2010. Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc. 15, 857–863 (2017). https://doi.org/10.1016/j.cgh.2016.10.039

4. Torres, J., Bonovas, S., Doherty, G., Kucharzik, T., Gisbert, J.P., Raine, T., Adamina, M., Armuzzi, A., Bachmann, O., Bager, P., Biancone, L., Bokemeyer, B., Bossuyt, P., Burisch, J., Collins, P., El-Hussuna, A., Ellul, P., Frei-Lanter, C., Furfaro, F., Gingert, C., Gionchetti, P., Gomollon, F., González-Lorenzo, M., Gordon, H., Hlavaty, T., Juillerat, P., Katsanos, K., Kopylov, U., Krustins, E., Lytras, T., Maaser, C., Magro, F., Kenneth Marshall, J., Myrelid, P., Pellino, G., Rosa, I., Sabino, J., Savarino, E., Spinelli, A., Stassen, L., Uzzan, M., Vavricka, S., Verstockt, B., Warusavitarne, J., Zmora, O., Fiorino, G., on behalf of the European Crohn’s and Colitis Organisation [ECCO]: ECCO guidelines on therapeutics in Crohn’s disease: medical treatment. J. Crohns Colitis 14, 4–22 (2020). https://doi.org/10.1093/ecco-jcc/jjz180

5. Raine, T., Bonovas, S., Burisch, J., Kucharzik, T., Adamina, M., Annese, V., Bachmann, O., Bettenworth, D., Chaparro, M., Czuber-Dochan, W., Eder, P., Ellul, P., Fidalgo, C., Fiorino, G., Gionchetti, P., Gisbert, J.P., Gordon, H., Hedin, C., Holubar, S., Iacucci, M., Karmiris, K., Katsanos, K., Kopylov, U., Lakatos, P.L., Lytras, T., Lyutakov, I., Noor, N., Pellino, G., Piovani, D., Savarino, E., Selvaggi, F., Verstockt, B., Spinelli, A., Panis, Y., Doherty, G.: ECCO guidelines on therapeutics in ulcerative colitis: medical treatment. J. Crohns Colitis 16, 2–17 (2022). https://doi.org/10.1093/ecco-jcc/jjab178

Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3